Fluticasone furoate/umeclidinium bromide/vilanterol

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is inhaled.[4][5][6]

Fluticasone furoate/umeclidinium bromide/vilanterol
Combination of
Fluticasone furoateCorticosteroid
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesTrelegy Ellipta, Elebrato Ellipta, Temybric Ellipta
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618017
License data
Pregnancy
category
    Routes of
    administration    		Inhalation
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    KEGG

    History

    Fluticasone furoate/umeclidinium bromide/vilanterol was approved for use in the United States in September 2017.[2] It was approved for use in the European Union in November 2017.[7][6][8]

    References
    1. "Fluticasone / umeclidinium / vilanterol (Trelegy Ellipta) Use During Pregnancy". Drugs.com. 13 June 2019. Retrieved 4 February 2020.
    2. "Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg) Inhalation Powder". U.S. Food and Drug Administration (FDA). 20 February 2018. Retrieved 4 February 2020.
    3. Lipson DA, Barnhart F, Brealey N, et al. (May 2018). "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD". N. Engl. J. Med. 378 (18): 1671–1680. doi:10.1056/NEJMoa1713901. PMID 29668352.
    4. "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 15 May 2019. Retrieved 4 February 2020.
    5. "Fluticasone, Umeclidinium, and Vilanterol (Professional Patient Advice)". Drugs.com. 25 November 2019. Retrieved 4 February 2020.
    6. "Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 30 October 2019. Retrieved 4 February 2020.
    7. "Trelegy Ellipta EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 4 February 2020.
    8. "Elebrato Ellipta EPAR". European Medicines Agency (EMA). Retrieved 19 June 2020.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.